Drugs / HGI-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05851105 | Oct 2022 → Dec 2026 expected | alpha thalassemia spectrum | Shenzhen Hemogen | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HGI-002 | “the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia” NCT05851105 ↗ |
| Action | Restore | “to restore α-globin expression” PMID 42200456 ↗ Jul 2026 |